# QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

> **NCT03169790** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **ImmunityBio, Inc.**

## Conditions studied

- Non Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** avelumab
- **BIOLOGICAL:** bevacizumab
- **DRUG:** capecitabine
- **DRUG:** cyclophosphamide
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** leucovorin
- **DRUG:** nab-paclitaxel
- **DRUG:** Lovaza
- **DRUG:** Oxaliplatin
- **DRUG:** rituximab
- **RADIATION:** Stereotactic Body Radiation Therapy
- **BIOLOGICAL:** ALT-803
- **BIOLOGICAL:** ETBX-061
- **BIOLOGICAL:** haNK

## Key facts

- **NCT ID:** NCT03169790
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2019-01
- **Final completion:** 2021-12-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial not initiated
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169790, "QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03169790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*